| Literature DB >> 29368422 |
Mariana Giaretta Mathias1, Carolina de Almeida Coelho-Landell1, Marie-Pier Scott-Boyer2, Sébastien Lacroix2, Melissa J Morine2,3, Roberta Garcia Salomão1, Roseli Borges Donegá Toffano1, Maria Olímpia Ribeiro do Vale Almada1, Joyce Moraes Camarneiro1, Elaine Hillesheim1, Tamiris Trevisan de Barros1, José Simon Camelo-Junior1, Esther Campos Giménez4, Karine Redeuil4, Alexandre Goyon4, Emmanuelle Bertschy4, Antoine Lévêques4, Jean-Marie Oberson4, Catherine Giménez4, Jerome Carayol5, Martin Kussmann5, Patrick Descombes5, Slyviane Métairon5, Colleen Fogarty Draper5, Nelly Conus5, Sara Colombo Mottaz4, Giovanna Zambianchi Corsini1, Stephanie Kazu Brandão Myoshi1, Mariana Mendes Muniz1, Lívia Cristina Hernandes6, Vinícius Paula Venâncio6, Lusania Maria Greggi Antunes6, Rosana Queiroz da Silva1, Taís Fontellas Laurito1, Isabela Ribeiro Rossi1, Raquel Ricci1, Jéssica Ré Jorge1, Mayara Leite Fagá1, Driele Cristina Gomes Quinhoneiro1, Mariana Chinarelli Reche1, Paula Vitória Sozza Silva1, Letícia Lima Falquetti1, Thaís Helena Alves da Cunha1, Thalia Manfrin Martins Deminice1, Tâmara Hambúrguer Tambellini1, Gabriela Cristina Arces de Souza1, Mariana Moraes de Oliveira1, Vicky Nogueira-Pileggi1, Marina Takemoto Matsumoto1, Corrado Priami2,3, Jim Kaput5, Jacqueline Pontes Monteiro1.
Abstract
SCOPE: Micronutrients are in small amounts in foods, act in concert, and require variable amounts of time to see changes in health and risk for disease. These first principles are incorporated into an intervention study designed to develop new experimental strategies for setting target recommendations for food bioactives for populations and individuals. METHODS ANDEntities:
Keywords: community-based participatory research; metabolic health; micronutrients; targeted and systems nutrition
Mesh:
Substances:
Year: 2018 PMID: 29368422 PMCID: PMC6120145 DOI: 10.1002/mnfr.201700613
Source DB: PubMed Journal: Mol Nutr Food Res ISSN: 1613-4125 Impact factor: 5.914
Figure 1Intervention design and overview of statistical analysis.
Baseline demographics, anthropometric, and clinical characteristics of participants in 2013 (n = 120) and 2014 (n = 133)
| Median v1 2013 | Q1–Q3 2013 | Median v1 2014 | Q1–Q3 2014 | Mann–Whitney | |
|---|---|---|---|---|---|
| n (outliers removed) | 120 | – | 133 | – | – |
| Sex (% female) | 57.1 | – | 54.9 | – | 6.8 × 10–01 |
| Tanner Score (for stages 1/2/3/4/5) | 12/52/40/12/3 | – | 7/33/60/30/3 | – | 1.7 × 10–03 |
| Age (years) | 12.1 | 11.1–12.9 | 12.52 | 11.7–13.5 | 1.5 × 10–04 |
| Weight (kg) | 44.6 | 36.5–57.8 | 45.5 | 38.5–59.1 | 3.3 × 10–01 |
| Height (cm) | 152.6 | 146.7–158.9 | 154.8 | 150.1–159.1 | 2.4 × 10–02 |
| BMI (kg m–2) | 19.2 | 16.3–22.5 | 19.0 | 16.6–23.4 | 8.9 × 10–01 |
| Waist circumference (cm) | 71.2 | 62.3–80.7 | 66.5 | 60.7–83.1 | 1.9 × 10–01 |
| Socio economic status (A1/A2/B1/B2/C1/C2/D) | 0/6/19/42/33/14/4 | – | 0/4/17/45/37/18/9 | – | 2.3 × 10–01 |
| Fat free mass (% of body weight) | 75.8 | 69.6–81.0 | 76.8 | 72.0–78.5 | 2.1 × 10–01 |
| Fat mass (% of body weight) | 24.1 | 19.8–30.0 | 23.2 | 18.8–30.0 | 2.4 × 10–01 |
| Glucose (mg dL–1) | 91.5 | 89.0 | 94 | 90.0 | 9.4 × 10–02 |
| Total cholesterol (mg dL–1) | 167 | 144.8–179.5 | 161 | 141–175.5 | 2.5 × 10–01 |
| LDL‐cholesterol (mg dL–1) | 106.5 | 86.8–116.5 | 100 | 83–106.8 | 2.1 × 10–01 |
| HDL‐cholesterol (mg dL–1) | 45.5 | 38.8–53.0 | 45 | 39.0–52.0 | 8.5 × 10–01 |
| Triglycerides (mg dL–1) | 68 | 48.0–82.3 | 60 | 46.0–90.8 | 1.4 × 10–01 |
| Mean corpuscular volume (fl) | 85.35 | 82.4–87.7 | 82.65 | 81.0–84.7 | < 1 × 10–02 |
| Mean corpuscular hemoglobin (pg) | 28.25 | 27.2–29 | 30.2 | 29.4–31.0 | < 1 × 10–02 |
| Basophils (% of total white blood cells) | 1.11 | 0.9–1.5 | 1.3 | 1.1–1.6 | < 1 × 10–02 |
| Platelets (number of cells x 103/μL) | 277 | 243–323 | 250 | 222–292 | < 1 × 10–02 |
| Albumin (g dL–1) | 4.5 | 4.4–4.7 | 4.5 | 4.4–4.7 | 9.8 × 10–01 |
| Calcium (mmol L–1) | 10.4 | 10.2 –10.5 | 10.8 | 10.3–10.5 | 1.7 × 10–16 |
| Iron (mg dL–1) | 93 | 73.0 –110.2 | 82 | 64.0–108.8 | 4.1 × 10–03 |
| Phosphate (mg dL–1) | 4.9 | 4.6–5.2 | 4.7 | 4.4–5.3 | 2.5 × 10–02 |
Significant difference between year marked by.
Baseline vitamin levels of participants in 2013 and 2014 and normal population rangesa
| Median 2013 | Q1–Q3 | Median 2014 | Q1–Q3 | Mean or Median Ref | 95% CI Ref | Age Year | Ref. | |
|---|---|---|---|---|---|---|---|---|
| Retinol (μg mL–1) (Vit A) | 0.3 ( | 0.3–0.4 | 0.4 | 0.3–0.5 | 0.36 | 0.36–0.37 | 6–11 |
|
| 0.47 | 0.45–0.48 | 12–19 | ||||||
| β–Carotene (μg mL–1) (Vit A precursor)* | 0.2 ( | 0.1–0.3 | 0.2 ( | 0.1–0.3 | 0.13 | 0.12–0.14 | 6–11 |
|
| 0.09 | 0.09–0.10 | 12–19 | ||||||
| Thiamine (Vit B1)* | 3.3 ( | 2.5–4.3 | 2.7 ( | 2.4–3.4 | 6.8 | 4.5–7.0 | 5–12 |
|
| Thiamine monophosphate (VitB1) | 8.5 ( | 6.0–11.4 | 10.0 | 7.6–14.1 | 6.8 | 5.8–9.0 | 5–12 |
|
| Thiamine triphosphate (VitB1)* | 4.6 ( | 4.07–5.28 | 3.3 ( | 2.8–3.8 | 9.0 | 8.4–10.7 | 5–12 |
|
| Riboflavin (VitB2)* | 10.8 ( | 8.0–15 | 12.1 ( | 8.2–16.5 | 20.1 ± 3.0 | 12.5–44.6 | 10–18 |
|
| Flavin adenine dinucleotide (VitB2) | 44.8 ( | 36.0–52.0 | 31.9 | 28.1–36.9 | 55.0 | 30.0–120.0 | 10–18 |
|
| Flavin mononucleotide (VitB2) | 10.6 ( | 8.2–13.7 | 8.0 | 6.7–10.2 | 13.0 ± 0.7 | 10.2–18.4 | 10–18 |
|
| Nicotinamide (VitB3) | 384.0 ( | 310.0–454.0 | 446.5 | 369–521.2 | 261.0 ± 217 | 20–34 |
| |
| Nudifloramide (VitB3) | 870.0 ( | 656.0–1305.0 | 943.5 ( | 691.0 –1397.0 | no ref | – | – | – |
| Pantothenic Acid (Vit B5) | 212.0 ( | 180.0–260.0 | 197.0 | 168.5–234.5 | no ref | – | – | – |
| Pyridoxic Acid (Vit B6) | 16.8 ( | 12.3–23.0 | 22.4 ( | 17.3–26.8 | 23.5 | 21.8–25.5 | 6–11 |
|
| 20.9 | 19.9–22.0 | 12–19 | ||||||
| Pyridoxal (Vit B6) | 7.3 ( | 5.9–9.4 | 7.9 ( | 6.2–9.5 | 21.1 | Range 8.8–58.7 | 1–18 |
|
| Pyridoxal 5′–phosphate (Vit B6) | 32.9 ( | 24.4–44.4 | 32.7 ( | 24.8–45.7 | 33.9 | Range 20.5–151 | 1–18 |
|
| Folate (ng mL–1) (Vit B9) | 4.9 (104) | 3.8–6.5 | 4.17 | 3.2–5.3 | 16.1 | 15.6–16.6 | 6–11 |
|
| 11.2 | 11.0–11.5 | 12–19 | ||||||
| 5–Methyl–tetrahydrofolic acid (Vit B9) | 21.1 ( | 12.4–29.6 | 20.8 ( | 10.0–31.1 | 91.0 | Low–High 26.4–219.7 | 11–15.9 |
|
|
| 3.6 ( | 2.7–4.7 | 7.3 ( | 4.7–9.8 | 11.9 ± 7.6 | – | 40 ± 1 |
|
| Cobalamin (pg mL–1) (Vit B12) | 371 ( | 290.8–464.5 | 410 | 319–550 | 728 | 713–743 | 6–11 |
|
| 510 | 499–521 | 12–19 | ||||||
| 25–hydroxycholecalciferol (25‐OH‐VitD3) | 64 ( | 54.7–82.4 | 70.2 ( | 56.8–81.2 | 63.8 | 61.6–66.1 | 6–11 |
|
| 55.1 | 52.4–58.0 | 12–19 | ||||||
| α‐tocopherol (μg mL–1) (Vit E) | 5.8 ( | 5.1–6.8 | 6.2 ( | 5.4–7.0 | 8.2 | 8.0–8.4 | 6–11 |
|
| 7.6–7.8 | 12–19 | |||||||
| γ‐tocopherol (μg mL–1) (Vit E) | 0.8 ( | 0.5–1.1 | 0.8 ( | 0.7–1.1 | 1.82 | 1.7–1.9 | 6–11 |
|
| 1.79 | 1.7–1.9 | 12–19 |
Although 26 circulating forms were analyzed, 22 had detectable levels or greater than 25% missing values at any time point.
All values are in nmol L–1. Values in parentheses represent the number of individuals included in analysis.
Mann–Whitney FDR adjusted p‐value < 0.05 versus 2013.
Mann–Whitney FDR adjusted p‐value < 0.1 versus 2013.
Values from58 are geometric means.
Variables were not considered in other analyses since they had more than 25% missing values at any time point.
Prevalence of deficiencies based on CDC cutoffsa
| Median 2013 | Q1–Q3 | Median 2014 | Q1–Q3 | Cutoff | Deficiencies 2013 (%) | Deficiencies 2014 (%) | |
|---|---|---|---|---|---|---|---|
| Folate (ng mL–1) | 4.9 | 3.8–6.5 | 4.17 | 3.2–5.3 | < 2 | 4.8 ( | 7.4 ( |
| Retinol (μg mL–1) | 0.3 | 0.3–0.4 | 0.4 | 0.3–0.5 | < 0.2 | 3.8 ( | 3.1 ( |
| α‐Tocopherol (μg mL–1) | 5.8 | 5.1–6.8 | 6.2 | 5.4–7.0 | < 5.0 | 23.1 ( | 15.5 ( |
| Vit B12 (pg mL–1) | 371 | 290.8–464.5 | 410 | 319–550 | < 200 | 7.6 ( | 2.1 ( |
| 25 OH VitD3 (nmol L–1) | 64 | 54.7–82.4 | 70.2 | 56.8–81.2 | < 50 | 10.4 ( | 13.5 ( |
From Appendix C of. [58] Note that CDC references are from serum rather than plasma used in this study.
Mann Whitney FDR adjusted p‐value < 0.05 vs. 2013.
Figure 2Admixture analysis. Influence of genetic ancestry on baseline vitamin levels. Ancestry markers from the Human Genome Diversity Project (HGDP) reference populations were used A) to identify admixture in data from unrelated participants from both years as per methods. To test whether linear regression between the ancestral components and baseline vitamin levels existed, a k = 5 model was used to the following covariates: trial year, sex, age, fat mass, and tanner score. Adjusted p‐value of 0.05 was used as significance threshold. B) Baseline TMP and Q1 (Europe) with estimate of regression coefficient (ERC) 4.57, C) baseline vitamin B12 and Q5 (Native American) ECR = 186.53, D) baseline folate and Q5 (Native American) ECR = 2.13, and E) folate response as ratio of V2/V1 and k5 (Native American) with ECR = 0.77.
Effect of intervention above regression to the mean for participants in 2013 and 2014
| Variable | Intervention 2013 | Washout 2013 | Intervention 2014 | Washout 2014 | ||||
|---|---|---|---|---|---|---|---|---|
| Effect |
| Effect |
| Effect |
| Effect |
| |
| Albumin (g dL–1) | –0.04 | 9.98 × 10–04 | –0.02 | 1.69 × 10–02 | –0.06 | 3.67 × 10–05 | –0.006 | 6.59 × 10–01 |
| Basophils (103 mm–3) | –0.08 | 2.48 × 10–02 | 0.06 | 1.16 × 10–01 | –0.08 | 1.37 × 10–02 | 0.006 | 8.57 × 10–01 |
| Calcium (mmol L–1) | –0.12 | 1.91 × 10–05 | 0.06 | 1.66 × 10–02 | –0.51 | 8.51 × 10–27 | –0.397 | 2.38 × 10–25 |
| Glucose (mg dL–1) | –2.06 | 4.78 × 10–04 | –0.46 | 2.83 × 10–01 | –1.37 | 8.74 × 10–03 | 0.306 | 5.61 × 10–01 |
| LDL‐Cholesterol (mg dL–1) | –8.08 | 8.30 × 10–10 | 0.11 | 9.27 × 10–01 | –4.17 | 3.70 × 10–04 | –4.823 | 7.64 × 10–05 |
| Mean corpuscular volume (fl) | 1.39 | 1.13 × 10–22 | –2.83 | 6.08 × 10–47 | 0.59 | 6.11 × 10–13 | –0.583 | 8.18 × 10–08 |
| FMN (nmol L–1) | 2.66 | 6.45 × 10–05 | –1.50 | 2.13 × 10–04 | 2.66 | 5.12 × 10–05 | –2.293 | 1.04 × 10–06 |
| Nudifloramide (nmol L–1) | 351.6 | 1.82 × 10–10 | –159.36 | 2.75 × 10–03 | 384.7 | 1.32 × 10–08 | –151.174 | 4.18 × 10–03 |
| Pantothenic Acid (nmol L–1) | 146.3 | 5.59 × 10–46 | –52.12 | 1.03 × 10–09 | 80.44 | 1.26 × 10–15 | –15.148 | 2.62 × 10–01 |
| Pyridoxal (nmol L–1) | 5.71 | 2.28 × 10–30 | –0.75 | 8.85 × 10–02 | 3.52 | 4.96 × 10–11 | –2.344 | 7.33 × 10–22 |
| α–Tocopherol (μg mL–1) | 0.47 | 2.54 × 10–04 | –0.94 | 7.86 × 10–16 | 0.59 | 2.90 × 10–04 | 0.006 | 9.67 × 10–01 |
| γ–Tocopherol (μg mL–1) | –0.20 | 1.31 × 10–09 | –0.01 | 5.38 × 10–01 | –0.12 | 9.58 × 10–05 | 0.095 | 7.23 × 10–03 |
| 5–methyltetrahydrofolic acid | 6.38 | 1.61 × 10–10 | –4.32 | 2.99 × 10–09 | 4.30 | 4.83 × 10–03 | 0.053 | 9.64 × 10–01 |
| Folate (ng mL–1) | 1.87 | 1.56 × 10–12 | –0.34 | 1.67 × 10–01 | 0.79 | 1.17 × 10–04 | –0.373 | 5.88 × 10–02 |
| Vitamin B12 (pg mL–1) | 69.87 | 1.49 × 10–04 | –45.18 | 2.39 × 10–04 | 69.07 | 1.45 × 10–07 | –21.144 | 1.83 × 10–01 |
All variables are in nmol L–1 except where noted otherwise.
Changes in Dyslipidemia from baseline to after interventiona
| Lipid | Age | Dyslipidemia Cutoff | Above Cutoff @ Baseline | Below Cutoff After Intervention | % Decrease |
|---|---|---|---|---|---|
| Total cholesterol | 9–13 | >200 mg dL–1 | 34 (280) | 19 (275) | 55.9 |
| LDL | 9–13 | >130 mg dL–1 | 42 (280) | 21 (275) | 50.0 |
| Triglyceride | 9 | >100 mg dL–1 | 1 (8) | 1 (7) | 100.0 |
| Triglyceride | 10–13 | >130 mg dL–1 | 21 (272) | 10 (268) | 47.8 |
Cutoffs from [57]. Number in parenthesis = sample number, no data for five samples after intervention. Percent decrease was calculated as number of individuals below cutoff after intervention divided by number of individuals above cutoff @ baseline. Percent increase was calculated from number of individuals above cutoff after intervention by number of individuals below cutoff at base line.
Figure 3Interindividual variability in response to intervention for LDL. We have identified individuals whose response exceeded normal within individual day‐to‐day variation (reported to be 10%62). Green: opposite‐responders, gray: non‐responders, and orange: responders to intervention.
Figure 4Comparison of elastic net and simple model performance across bootstrapped analyses. A) Vitamin and B) clinical variable response. Model performance is shown for each response variable and modeling approach. Performance is measured as a correlation between predicted and observed 2014 response to intervention.
Figure 5Modeling for nicotinamide response. A) Fitted coefficients and frequency (in parentheses) of predictor variables across 1000 bootstrapped analyses. B) Observed versus predicted response to intervention across bootstrapped analyses. Each boxplot corresponds to an individual participant, and thus shows variation in predicted response for each individual across the bootstrapped analyses.